Literature DB >> 35768075

Transporters in Regulatory Science: Notable Contributions from Dr. Giacomini in the Past Two Decades.

Lei Zhang1, Qi Liu2, Shiew-Mei Huang2, Robert Lionberger3.   

Abstract

Transporters govern the access of molecules to cells or their exit from cells, thereby controlling the overall distribution of drugs to their intracellular site of action. Clinically relevant drug-drug interactions mediated by transporters are of increasing interest in drug development. Drug transporters, acting alone or in concert with drug metabolizing enzymes, can play an important role in modulating drug absorption, distribution, metabolism, and excretion, thus affecting the pharmacokinetics and/or pharmacodynamics of a drug. Dr. Kathy Giacomini from the University of California, San Francisco is one of the world leaders in transporters and pharmacogenetics with key contributions to transporter science. Her contributions to transporter science are noteworthy. This review paper will summarize Dr. Giacomini's key contributions and influence on transporters in regulatory science in the past two decades. Regulatory science research highlighted in this review covers various aspects of transporter science including understanding the effect of renal impairment on transporters, transporter ontogeny, biomarkers for transporters, and interactions of excipients with transporters affecting drug absorption. Significance Statement This review paper highlights Dr. Giacomini's key contributions and influence on transporters in regulatory science in the past two decades. She has been at the cutting edge of science pertaining to drug transport, drug disposition, and regulatory science, leading to new era of translational sciences pertaining to drug disposition and transporter biology. Her research has and will continue to bring enormous impact on gaining new knowledge in guiding drug development and inspire scientists from all sectors in the field.
Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Keywords:  Absorption; renal transport; transporters

Year:  2022        PMID: 35768075      PMCID: PMC9488972          DOI: 10.1124/dmd.121.000706

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.579


  57 in total

Review 1.  Drug interaction studies: study design, data analysis, and implications for dosing and labeling.

Authors:  S-M Huang; R Temple; D C Throckmorton; L J Lesko
Journal:  Clin Pharmacol Ther       Date:  2007-02       Impact factor: 6.875

2.  Transporters in drug development and clinical pharmacology.

Authors:  K M Giacomini; S-M Huang
Journal:  Clin Pharmacol Ther       Date:  2013-07       Impact factor: 6.875

3.  Transporters in drug development: advancing on the Critical Path.

Authors:  Shiew-Mei Huang; Janet Woodcock
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

4.  The US Food and Drug Administration Centers for Regulatory Science and Innovation: Current Activities and Future Promise to Accelerate Innovations.

Authors:  Frank F Weichold
Journal:  Clin Pharmacol Ther       Date:  2019-02-10       Impact factor: 6.875

5.  PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters.

Authors:  C-H Hsueh; V Hsu; P Zhao; L Zhang; K M Giacomini; S-M Huang
Journal:  Clin Pharmacol Ther       Date:  2017-07-24       Impact factor: 6.875

Review 6.  Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium.

Authors:  Xiaoyan Chu; Mingxiang Liao; Hong Shen; Kenta Yoshida; Arik A Zur; Vikram Arya; Aleksandra Galetin; Kathleen M Giacomini; Imad Hanna; Hiroyuki Kusuhara; Yurong Lai; David Rodrigues; Yuichi Sugiyama; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Clin Pharmacol Ther       Date:  2018-11       Impact factor: 6.875

7.  ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays.

Authors:  C A Lee; J C Kalvass; A Galetin; M J Zamek-Gliszczynski
Journal:  Clin Pharmacol Ther       Date:  2014-09       Impact factor: 6.875

Review 8.  Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group.

Authors:  K L R Brouwer; L M Aleksunes; B Brandys; G P Giacoia; G Knipp; V Lukacova; B Meibohm; S K Nigam; M Rieder; S N de Wildt
Journal:  Clin Pharmacol Ther       Date:  2015-09       Impact factor: 6.875

9.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

10.  Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1.

Authors:  Jayabharathi Vaidyanathan; Kenta Yoshida; Vikram Arya; Lei Zhang
Journal:  J Clin Pharmacol       Date:  2016-07       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.